Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have each demonstrated cardiovascular and renal benefits across high-risk populations, including those with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD). This evidence concerns the gene SLC5A2 and chronic kidney disease.